Search

Search Results

• 

  32 | Tebentafusp in metastatic uveal melanoma: 3 years of real world data and insights from liquid biopsy Luisa Piccin¹, Maria Chiara Scaini², Valentina Salizzato¹, Cristina Catoni², Elisabetta Di Liso¹, Alice Menichetti¹, Chiara Cacco^1|4, Chiara Gottardi^1|4, Francesca Di Sarra³, Marina Coppola³, Valentina Guarneri^1|4, Jacopo Pigozzo¹ | ¹Medical Oncology 2 - Veneto Institute of Oncology IOV-IRCCS; ²Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS; ³Pharmacy Unit - Veneto Institute of Oncology IOV-IRCCS; ⁴Department of Surgery, Oncology and Gastroenterology, University of Padova, Italy.

  Italian Melanoma Intergroup

  11-12-2025

  https://doi.org/10.4081/dr.2025.10774

  258

• Omalizumab for treatment of refractory urticaria in a patient with metastatic uveal melanoma receiving tebentafusp

  Faith Simmonds, Veronica Kashua, Diana McDonnell, Mariam El-Ashmawy, Alexandra J. Coromilas

  06-05-2026

  https://doi.org/10.4081/dr.2026.10366

  0

  PDF: 0